Using global statistical tests in long-term Parkinson's disease clinical trials

Peng Huang, Christopher G. Goetz, Robert F. Woolson, Barbara Tilley, Douglas Kerr, Yuko Palesch, Jordan Elm, Bernard Ravina, Kenneth J. Bergmann, Karl Kieburtz

Research output: Contribution to journalArticle

Abstract

Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the longterm decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact, and we highlight the novel Global Statistical Test (GST) methodology. We compare the GST to other multivariate approaches using data from two PD trials. In one trial where the treatment showed consistent improvement on all primary and secondary outcomes, the GST was more powerful than other methods in demonstrating significant improvement. In the trial where treatment induced both improvement and deterioration in key outcomes, the GST failed to demonstrate statistical evidence even though other techniques showed signifi-cant improvement. Based on the statistical properties of the GST and its relevance to overall treatment benefit, the GST appears particularly well suited for a disease like PD where disability and impairment reflect dysfunction of diverse brain systems and where both disease and treatment side effects impact quality of life. In future long term trials, use of GST for primary statistical analysis would allow the assessment of clinically relevant outcomes rather than the artificial selection of a single primary outcome.

Original languageEnglish (US)
Pages (from-to)1732-1739
Number of pages8
JournalMovement disorders : official journal of the Movement Disorder Society
Volume24
Issue number12
DOIs
StatePublished - Sep 15 2009

Fingerprint

Parkinson Disease
Clinical Trials
Quality of Life
Brain

Keywords

  • Global treatment effect
  • Multiple outcomes

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Using global statistical tests in long-term Parkinson's disease clinical trials. / Huang, Peng; Goetz, Christopher G.; Woolson, Robert F.; Tilley, Barbara; Kerr, Douglas; Palesch, Yuko; Elm, Jordan; Ravina, Bernard; Bergmann, Kenneth J.; Kieburtz, Karl.

In: Movement disorders : official journal of the Movement Disorder Society, Vol. 24, No. 12, 15.09.2009, p. 1732-1739.

Research output: Contribution to journalArticle

Huang, P, Goetz, CG, Woolson, RF, Tilley, B, Kerr, D, Palesch, Y, Elm, J, Ravina, B, Bergmann, KJ & Kieburtz, K 2009, 'Using global statistical tests in long-term Parkinson's disease clinical trials', Movement disorders : official journal of the Movement Disorder Society, vol. 24, no. 12, pp. 1732-1739. https://doi.org/10.1002/mds.22645
Huang, Peng ; Goetz, Christopher G. ; Woolson, Robert F. ; Tilley, Barbara ; Kerr, Douglas ; Palesch, Yuko ; Elm, Jordan ; Ravina, Bernard ; Bergmann, Kenneth J. ; Kieburtz, Karl. / Using global statistical tests in long-term Parkinson's disease clinical trials. In: Movement disorders : official journal of the Movement Disorder Society. 2009 ; Vol. 24, No. 12. pp. 1732-1739.
@article{bd07852763fb4050ae8723d92fed4f97,
title = "Using global statistical tests in long-term Parkinson's disease clinical trials",
abstract = "Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the longterm decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact, and we highlight the novel Global Statistical Test (GST) methodology. We compare the GST to other multivariate approaches using data from two PD trials. In one trial where the treatment showed consistent improvement on all primary and secondary outcomes, the GST was more powerful than other methods in demonstrating significant improvement. In the trial where treatment induced both improvement and deterioration in key outcomes, the GST failed to demonstrate statistical evidence even though other techniques showed signifi-cant improvement. Based on the statistical properties of the GST and its relevance to overall treatment benefit, the GST appears particularly well suited for a disease like PD where disability and impairment reflect dysfunction of diverse brain systems and where both disease and treatment side effects impact quality of life. In future long term trials, use of GST for primary statistical analysis would allow the assessment of clinically relevant outcomes rather than the artificial selection of a single primary outcome.",
keywords = "Global treatment effect, Multiple outcomes",
author = "Peng Huang and Goetz, {Christopher G.} and Woolson, {Robert F.} and Barbara Tilley and Douglas Kerr and Yuko Palesch and Jordan Elm and Bernard Ravina and Bergmann, {Kenneth J.} and Karl Kieburtz",
year = "2009",
month = "9",
day = "15",
doi = "10.1002/mds.22645",
language = "English (US)",
volume = "24",
pages = "1732--1739",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Using global statistical tests in long-term Parkinson's disease clinical trials

AU - Huang, Peng

AU - Goetz, Christopher G.

AU - Woolson, Robert F.

AU - Tilley, Barbara

AU - Kerr, Douglas

AU - Palesch, Yuko

AU - Elm, Jordan

AU - Ravina, Bernard

AU - Bergmann, Kenneth J.

AU - Kieburtz, Karl

PY - 2009/9/15

Y1 - 2009/9/15

N2 - Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the longterm decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact, and we highlight the novel Global Statistical Test (GST) methodology. We compare the GST to other multivariate approaches using data from two PD trials. In one trial where the treatment showed consistent improvement on all primary and secondary outcomes, the GST was more powerful than other methods in demonstrating significant improvement. In the trial where treatment induced both improvement and deterioration in key outcomes, the GST failed to demonstrate statistical evidence even though other techniques showed signifi-cant improvement. Based on the statistical properties of the GST and its relevance to overall treatment benefit, the GST appears particularly well suited for a disease like PD where disability and impairment reflect dysfunction of diverse brain systems and where both disease and treatment side effects impact quality of life. In future long term trials, use of GST for primary statistical analysis would allow the assessment of clinically relevant outcomes rather than the artificial selection of a single primary outcome.

AB - Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the longterm decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact, and we highlight the novel Global Statistical Test (GST) methodology. We compare the GST to other multivariate approaches using data from two PD trials. In one trial where the treatment showed consistent improvement on all primary and secondary outcomes, the GST was more powerful than other methods in demonstrating significant improvement. In the trial where treatment induced both improvement and deterioration in key outcomes, the GST failed to demonstrate statistical evidence even though other techniques showed signifi-cant improvement. Based on the statistical properties of the GST and its relevance to overall treatment benefit, the GST appears particularly well suited for a disease like PD where disability and impairment reflect dysfunction of diverse brain systems and where both disease and treatment side effects impact quality of life. In future long term trials, use of GST for primary statistical analysis would allow the assessment of clinically relevant outcomes rather than the artificial selection of a single primary outcome.

KW - Global treatment effect

KW - Multiple outcomes

UR - http://www.scopus.com/inward/record.url?scp=70450044682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450044682&partnerID=8YFLogxK

U2 - 10.1002/mds.22645

DO - 10.1002/mds.22645

M3 - Article

VL - 24

SP - 1732

EP - 1739

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 12

ER -